Pollution-open-access-journals
Being a multidisciplinary journal, International community for
pollution serves with all aspects of
environmental sciences. The journal is being published seasonally. In this route, environmentalist disciplines are welcomed to contribute their knowledge and knowledge. Journal of
pollution publishes
research articles and reviews encompassed within the ever-increasing borders of
environmental sciences. These include Terrestrial and Aquatic Biology and Ecology, Geosciences, Atmospheric Chemistry,
Environmental Microbiology and Bio-based Energy Sources,
Phytoremediation and
Ecosystem Restoration,
Environmental Analyses and Monitoring, Assessment of Risks and Interactions of Pollutants within the Environment,
Conservation Biology and Sustainable Agriculture, Impact of Chemicals/Pollutants on Human and Animal
Health and Emerging pollutants. Accordingly, top quality research works falling within mentioned scopes are welcomed. Submitted papers may be theoretical, interpretative or experimental.
Pollutants contact all pieces of the planet. It influences our wellbeing through the food we eat, the water we drink and the air we relax. The WHO assesses that 23 per-cents of all passing around the world – adding up to 12.6 million out of 2012 - are because of natural dangers, and contamination is the biggest ecological reason for sickness and sudden passing on the planet today. Low-pay and centre pay nations endure the worst part of
pollution related sicknesses, with an unbalanced effect on kids, ladies and the most defenceless. There are numerous examples of overcoming adversity in tending to pollution, as innovations and the executives methodologies advance. In any case,
pollution stays inescapable and keeps on representing an immediate danger to human wellbeing and the earth.
High Impact List of Articles
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection
Christoph Honer zu Siederdisse & Markus Cornberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection
Christoph Honer zu Siederdisse & Markus Cornberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection
Christoph Honer zu Siederdisse & Markus Cornberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection
Christoph Honer zu Siederdisse & Markus Cornberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection
Christoph Honer zu Siederdisse & Markus Cornberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection
Christoph Honer zu Siederdisse & Markus Cornberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection
Christoph Honer zu Siederdisse & Markus Cornberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection
Christoph Honer zu Siederdisse & Markus Cornberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
Relevant Topics in Clinical